A briefing document released by the FDA ahead of the Vaccine and Related Biological Products Advisory Committee revealed that a phase 1 trial evaluating two RSV vaccines in infants aged 5 to 8 months was paused in July after five severe cases of RSV-related illness were reported among infants receiving the vaccine candidates.
The trial, which tested two Moderna RSV vaccines, mRNA-1365 and mRNA-1345, found that infants who received a 15-microgram dose of either vaccine had a higher incidence of severe lower respiratory tract infections compared to those who received a placebo. Five of six infants required hospitalization, with one needing mechanical ventilation.
The safety signal prompted Moderna to halt enrollment in the trial and the FDA subsequently issued a clinical hold.
VRBPAC will review the safety data and discuss implications for the future development of RSV vaccines for infants Dec. 12.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.